
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (32): 4055-4061.DOI: 10.12114/j.issn.1007-9572.2024.0704
Special Issue: 内分泌代谢性疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2025-02-10
Revised:2025-07-15
Published:2025-11-15
Online:2025-09-23
Contact:
LI Xiaohong, GUO Ying
通讯作者:
励晓红, 郭莺
作者简介:作者贡献:
张磊负责资料收集、整理、分析和论文撰写;张环宇负责论文的修订;陈凯悦负责资料整理和绘制图表;励晓红、郭莺负责提出研究目标、文章的构思和设计,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0704
| 类别 | 例数 | 性别 | 年龄 | FPG | HbA1c | 2 hPG | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 女 | 男 | 35~44岁 | 45~54岁 | 55~64岁 | 65~74岁 | 正常 | 异常 | 正常 | 异常 | 正常 | 异常 | ||
| 正常血糖 | 312 | 246(78.9) | 66(21.1) | 111(35.6) | 106(34.0) | 60(19.2) | 35(11.2) | 312(100.0) | 0 | 168(53.8) | 144(46.2) | 312(100.0) | 0 |
| 糖尿病前期 | 141 | 95(67.4) | 46(32.6) | 21(14.9) | 45(31.9) | 30(21.3) | 45(31.9) | 129(91.5) | 12(8.5) | 39(27.7) | 102(72.3) | 2(1.4) | 139(98.6) |
| 2型糖尿病 | 74 | 44(59.5) | 30(40.5) | 8(10.8) | 15(20.3) | 28(37.8) | 23(31.1) | 24(32.4) | 50(67.6) | 2(2.7) | 72(97.3) | 1(1.4) | 73(98.6) |
| χ2值 | 14.57 | 63.76 | 265.02 | 76.96 | 514.70 | ||||||||
| P值 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
Table 1 Glucose metabolism screening results of 527 participants
| 类别 | 例数 | 性别 | 年龄 | FPG | HbA1c | 2 hPG | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 女 | 男 | 35~44岁 | 45~54岁 | 55~64岁 | 65~74岁 | 正常 | 异常 | 正常 | 异常 | 正常 | 异常 | ||
| 正常血糖 | 312 | 246(78.9) | 66(21.1) | 111(35.6) | 106(34.0) | 60(19.2) | 35(11.2) | 312(100.0) | 0 | 168(53.8) | 144(46.2) | 312(100.0) | 0 |
| 糖尿病前期 | 141 | 95(67.4) | 46(32.6) | 21(14.9) | 45(31.9) | 30(21.3) | 45(31.9) | 129(91.5) | 12(8.5) | 39(27.7) | 102(72.3) | 2(1.4) | 139(98.6) |
| 2型糖尿病 | 74 | 44(59.5) | 30(40.5) | 8(10.8) | 15(20.3) | 28(37.8) | 23(31.1) | 24(32.4) | 50(67.6) | 2(2.7) | 72(97.3) | 1(1.4) | 73(98.6) |
| χ2值 | 14.57 | 63.76 | 265.02 | 76.96 | 514.70 | ||||||||
| P值 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
| FPG筛查界值(mmol/L) | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) | 约登指数 |
|---|---|---|---|---|---|
| 5.0 | 74.42 | 66.99 | 60.84 | 79.17 | 0.414 |
| 5.1 | 65.12 | 79.81 | 68.97 | 76.85 | 0.449 |
| 5.2 | 59.07 | 86.54 | 75.15 | 75.42 | 0.456 |
| 5.3 | 59.07 | 86.54 | 75.15 | 75.42 | 0.456 |
| 5.4 | 54.42 | 91.67 | 81.82 | 74.48 | 0.461 |
| 5.5 | 49.77 | 93.27 | 83.59 | 72.93 | 0.430 |
| 5.6 | 41.40 | 97.12 | 90.82 | 70.63 | 0.385 |
| 5.7 | 35.81 | 98.40 | 93.90 | 68.99 | 0.342 |
| 5.8 | 35.81 | 98.40 | 93.90 | 68.99 | 0.342 |
| 5.9 | 33.02 | 99.68 | 98.61 | 68.35 | 0.327 |
| 6.0 | 31.16 | 99.68 | 98.53 | 67.76 | 0.308 |
| 6.1 | 28.84 | 100.00 | 100.00 | 67.10 | 0.288 |
Table 2 Comparison of screening effects using fasting plasma glucose as a detection indicator
| FPG筛查界值(mmol/L) | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) | 约登指数 |
|---|---|---|---|---|---|
| 5.0 | 74.42 | 66.99 | 60.84 | 79.17 | 0.414 |
| 5.1 | 65.12 | 79.81 | 68.97 | 76.85 | 0.449 |
| 5.2 | 59.07 | 86.54 | 75.15 | 75.42 | 0.456 |
| 5.3 | 59.07 | 86.54 | 75.15 | 75.42 | 0.456 |
| 5.4 | 54.42 | 91.67 | 81.82 | 74.48 | 0.461 |
| 5.5 | 49.77 | 93.27 | 83.59 | 72.93 | 0.430 |
| 5.6 | 41.40 | 97.12 | 90.82 | 70.63 | 0.385 |
| 5.7 | 35.81 | 98.40 | 93.90 | 68.99 | 0.342 |
| 5.8 | 35.81 | 98.40 | 93.90 | 68.99 | 0.342 |
| 5.9 | 33.02 | 99.68 | 98.61 | 68.35 | 0.327 |
| 6.0 | 31.16 | 99.68 | 98.53 | 67.76 | 0.308 |
| 6.1 | 28.84 | 100.00 | 100.00 | 67.10 | 0.288 |
| HbA1c筛查界值 | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) | 约登指数 |
|---|---|---|---|---|---|
| 5.0 | 100.00 | 1.28 | 41.11 | 100.00 | 0.013 |
| 5.1 | 99.53 | 5.45 | 42.04 | 94.44 | 0.050 |
| 5.2 | 99.07 | 7.37 | 42.43 | 92.00 | 0.064 |
| 5.3 | 99.07 | 7.37 | 42.43 | 92.00 | 0.064 |
| 5.4 | 98.14 | 13.14 | 43.78 | 91.11 | 0.113 |
| 5.5 | 97.21 | 20.51 | 45.73 | 91.43 | 0.177 |
| 5.6 | 88.84 | 40.71 | 50.80 | 84.11 | 0.295 |
| 5.7 | 82.33 | 53.85 | 55.14 | 81.55 | 0.362 |
| 5.8 | 82.33 | 53.85 | 55.14 | 81.55 | 0.362 |
| 5.9 | 73.95 | 65.71 | 59.77 | 78.54 | 0.370 |
| 6.0 | 66.05 | 75.00 | 64.55 | 76.22 | 0.411 |
| 6.1 | 51.63 | 91.67 | 81.02 | 73.33 | 0.433 |
| 6.2 | 46.98 | 94.87 | 86.32 | 72.20 | 0.419 |
| 6.3 | 46.98 | 94.87 | 86.32 | 72.20 | 0.419 |
| 6.4 | 43.72 | 97.12 | 91.26 | 71.46 | 0.408 |
| 6.5 | 39.07 | 98.08 | 93.33 | 70.02 | 0.372 |
Table 3 Comparison of screening effects using fasting plasma glucose and glycated hemoglobin as detection indicators
| HbA1c筛查界值 | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) | 约登指数 |
|---|---|---|---|---|---|
| 5.0 | 100.00 | 1.28 | 41.11 | 100.00 | 0.013 |
| 5.1 | 99.53 | 5.45 | 42.04 | 94.44 | 0.050 |
| 5.2 | 99.07 | 7.37 | 42.43 | 92.00 | 0.064 |
| 5.3 | 99.07 | 7.37 | 42.43 | 92.00 | 0.064 |
| 5.4 | 98.14 | 13.14 | 43.78 | 91.11 | 0.113 |
| 5.5 | 97.21 | 20.51 | 45.73 | 91.43 | 0.177 |
| 5.6 | 88.84 | 40.71 | 50.80 | 84.11 | 0.295 |
| 5.7 | 82.33 | 53.85 | 55.14 | 81.55 | 0.362 |
| 5.8 | 82.33 | 53.85 | 55.14 | 81.55 | 0.362 |
| 5.9 | 73.95 | 65.71 | 59.77 | 78.54 | 0.370 |
| 6.0 | 66.05 | 75.00 | 64.55 | 76.22 | 0.411 |
| 6.1 | 51.63 | 91.67 | 81.02 | 73.33 | 0.433 |
| 6.2 | 46.98 | 94.87 | 86.32 | 72.20 | 0.419 |
| 6.3 | 46.98 | 94.87 | 86.32 | 72.20 | 0.419 |
| 6.4 | 43.72 | 97.12 | 91.26 | 71.46 | 0.408 |
| 6.5 | 39.07 | 98.08 | 93.33 | 70.02 | 0.372 |
| FPG筛查界值(mmo/L) | 正确发现糖代谢异常人数(例) | 需口服糖耐量试验人数(例) | 口服糖耐量试验阳性率(%) | 检测成本(元) | 时间机会成本(元) | 筛查成本(元) | 成本效果比(元/人) |
|---|---|---|---|---|---|---|---|
| 5.0 | 160 | 263 | 60.84 | 11 314 | 36 820 | 48 134 | 300.84 |
| 5.1 | 140 | 203 | 68.97 | 9 334 | 28 420 | 37 754 | 269.67 |
| 5.2 | 127 | 169 | 75.15 | 8 212 | 23 660 | 31 872 | 250.96 |
| 5.3 | 127 | 169 | 75.15 | 8 212 | 23 660 | 31 872 | 250.96 |
| 5.4 | 117 | 143 | 81.82 | 7 354 | 20 020 | 27 374 | 233.97 |
| 5.5 | 107 | 128 | 83.59 | 6 859 | 17 920 | 24 779 | 231.58 |
| 5.6 | 89 | 98 | 90.82 | 5 869 | 13 720 | 19 589 | 220.10 |
| 5.7 | 77 | 82 | 93.90 | 5 341 | 11 480 | 16 821 | 218.45 |
| 5.8 | 77 | 82 | 93.90 | 5 341 | 11 480 | 16 821 | 218.45 |
| 5.9 | 71 | 72 | 98.61 | 5 011 | 10 080 | 15 091 | 212.55 |
| 6.0 | 67 | 68 | 98.53 | 4 879 | 9 520 | 14 399 | 214.91 |
| 6.1 | 62 | 62 | 100.00 | 4 681 | 8 680 | 13 361 | 215.50 |
Table 4 Cost effectiveness comparison of fasting plasma glucose as a detection indicator
| FPG筛查界值(mmo/L) | 正确发现糖代谢异常人数(例) | 需口服糖耐量试验人数(例) | 口服糖耐量试验阳性率(%) | 检测成本(元) | 时间机会成本(元) | 筛查成本(元) | 成本效果比(元/人) |
|---|---|---|---|---|---|---|---|
| 5.0 | 160 | 263 | 60.84 | 11 314 | 36 820 | 48 134 | 300.84 |
| 5.1 | 140 | 203 | 68.97 | 9 334 | 28 420 | 37 754 | 269.67 |
| 5.2 | 127 | 169 | 75.15 | 8 212 | 23 660 | 31 872 | 250.96 |
| 5.3 | 127 | 169 | 75.15 | 8 212 | 23 660 | 31 872 | 250.96 |
| 5.4 | 117 | 143 | 81.82 | 7 354 | 20 020 | 27 374 | 233.97 |
| 5.5 | 107 | 128 | 83.59 | 6 859 | 17 920 | 24 779 | 231.58 |
| 5.6 | 89 | 98 | 90.82 | 5 869 | 13 720 | 19 589 | 220.10 |
| 5.7 | 77 | 82 | 93.90 | 5 341 | 11 480 | 16 821 | 218.45 |
| 5.8 | 77 | 82 | 93.90 | 5 341 | 11 480 | 16 821 | 218.45 |
| 5.9 | 71 | 72 | 98.61 | 5 011 | 10 080 | 15 091 | 212.55 |
| 6.0 | 67 | 68 | 98.53 | 4 879 | 9 520 | 14 399 | 214.91 |
| 6.1 | 62 | 62 | 100.00 | 4 681 | 8 680 | 13 361 | 215.50 |
| HbA1c筛查界值(%) | 正确发现糖代谢异常人数(例) | 需口服糖耐量试验人数(例) | 口服糖耐量试验阳性率(%) | 检测成本(元) | 时间机会成本(元) | 筛查成本(元) | 成本效果比(元/人) |
|---|---|---|---|---|---|---|---|
| 5.0 | 215 | 523 | 41.11 | 46 864 | 73 220 | 120 084 | 558.53 |
| 5.1 | 214 | 509 | 42.04 | 46 402 | 71 260 | 117 662 | 549.82 |
| 5.2 | 213 | 502 | 42.43 | 46 171 | 70 280 | 116 451 | 546.72 |
| 5.3 | 213 | 502 | 42.43 | 46 171 | 70 280 | 116 451 | 546.72 |
| 5.4 | 211 | 482 | 43.78 | 45 511 | 67 480 | 112 991 | 535.50 |
| 5.5 | 209 | 457 | 45.73 | 44 686 | 63 980 | 108 666 | 519.93 |
| 5.6 | 191 | 376 | 50.80 | 42 013 | 52 640 | 94 653 | 495.57 |
| 5.7 | 177 | 321 | 55.14 | 40 198 | 44 940 | 85 138 | 481.01 |
| 5.8 | 177 | 321 | 55.14 | 40 198 | 44 940 | 85 138 | 481.01 |
| 5.9 | 159 | 266 | 59.77 | 38 383 | 37 240 | 75 623 | 475.62 |
| 6.0 | 142 | 220 | 64.55 | 36 865 | 30 800 | 67 665 | 476.51 |
| 6.1 | 111 | 137 | 81.02 | 34 126 | 19 180 | 53 306 | 480.23 |
| 6.2 | 101 | 117 | 86.32 | 33 466 | 16 380 | 49 846 | 493.52 |
| 6.3 | 101 | 117 | 86.32 | 33 466 | 16 380 | 49 846 | 493.52 |
| 6.4 | 94 | 103 | 91.26 | 33 004 | 14 420 | 47 424 | 504.51 |
| 6.5 | 84 | 90 | 93.33 | 32 575 | 12 600 | 45 175 | 537.80 |
Table 5 Cost effectiveness comparison of fasting plasma glucose and glycated hemoglobin as detection indicators
| HbA1c筛查界值(%) | 正确发现糖代谢异常人数(例) | 需口服糖耐量试验人数(例) | 口服糖耐量试验阳性率(%) | 检测成本(元) | 时间机会成本(元) | 筛查成本(元) | 成本效果比(元/人) |
|---|---|---|---|---|---|---|---|
| 5.0 | 215 | 523 | 41.11 | 46 864 | 73 220 | 120 084 | 558.53 |
| 5.1 | 214 | 509 | 42.04 | 46 402 | 71 260 | 117 662 | 549.82 |
| 5.2 | 213 | 502 | 42.43 | 46 171 | 70 280 | 116 451 | 546.72 |
| 5.3 | 213 | 502 | 42.43 | 46 171 | 70 280 | 116 451 | 546.72 |
| 5.4 | 211 | 482 | 43.78 | 45 511 | 67 480 | 112 991 | 535.50 |
| 5.5 | 209 | 457 | 45.73 | 44 686 | 63 980 | 108 666 | 519.93 |
| 5.6 | 191 | 376 | 50.80 | 42 013 | 52 640 | 94 653 | 495.57 |
| 5.7 | 177 | 321 | 55.14 | 40 198 | 44 940 | 85 138 | 481.01 |
| 5.8 | 177 | 321 | 55.14 | 40 198 | 44 940 | 85 138 | 481.01 |
| 5.9 | 159 | 266 | 59.77 | 38 383 | 37 240 | 75 623 | 475.62 |
| 6.0 | 142 | 220 | 64.55 | 36 865 | 30 800 | 67 665 | 476.51 |
| 6.1 | 111 | 137 | 81.02 | 34 126 | 19 180 | 53 306 | 480.23 |
| 6.2 | 101 | 117 | 86.32 | 33 466 | 16 380 | 49 846 | 493.52 |
| 6.3 | 101 | 117 | 86.32 | 33 466 | 16 380 | 49 846 | 493.52 |
| 6.4 | 94 | 103 | 91.26 | 33 004 | 14 420 | 47 424 | 504.51 |
| 6.5 | 84 | 90 | 93.33 | 32 575 | 12 600 | 45 175 | 537.80 |
| [1] |
葛均波,王辰,王建安. 内科学[M]. 10版. 北京:人民卫生出版社,2024.
|
| [2] |
中华医学会内分泌学分会,中华医学会糖尿病学分会,中国医师协会内分泌代谢科医师分会,等. 中国成人糖尿病前期干预的专家共识(2023版)[J]. 中华糖尿病杂志,2023,15(6):484-494. DOI:10.3760/cma.j.cn115791-20230509-00188.
|
| [3] |
|
| [4] |
|
| [5] |
黎衍云,杨沁平,吴菲,等. 上海市35岁及以上居民2型糖尿病流行现状及影响因素分析[J]. 中国慢性病预防与控制,2021,29(10):729-734. DOI:10.16386/j.cjpccd.issn.1004-6194.2021.10.003.
|
| [6] |
刘雪婷,石金霞,李海燕,等. 深圳社区糖尿病高危人群主动筛查方法探讨[J]. 深圳中西医结合杂志,2022,32(11):21-25. DOI:10.16458/j.cnki.1007-0893.2022.11.006.
|
| [7] |
王莉,黄翰宇,沈娟,等. 糖化血红蛋白检测在糖尿病诊断中的应用进展[J]. 世界最新医学信息文摘,2018,18(2):33,35. DOI:10.19613/j.cnki.1671-3141.2018.02.018.
|
| [8] |
卢琦,杨进,乐云逸,等. 糖调节受损与糖化血红蛋白定义的糖尿病前期之间的临床特征比较[J]. 中华糖尿病杂志,2020,12(11):904-909. DOI:10.3760/cma.j.cn115791-20200316-00095.
|
| [9] |
周翔海,纪立农. 空腹血糖和糖化血红蛋白用于筛查糖尿病的研究[J]. 中华糖尿病杂志,2005,13(3):203-205. DOI:10.3321/j.issn:1006-6187.2005.03.018.
|
| [10] |
张景义,郭静,董钊,等. 糖化血红蛋白和空腹血糖早期诊断糖尿病的截点研究[J]. 中国全科医学,2017,20(7):808-811,822. DOI:10.3969/j.issn.1007-9572.2017.07.010.
|
| [11] |
中华医学会糖尿病学分会,朱大龙. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409. DOI:10.3760/cma.j.cn115791-20210221-00095.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] | |
| [16] |
马辰星,许颖,康向辉,等. 空腹血糖诊断糖尿病截点的探讨与评价[J]. 中国全科医学,2014,17(17):1943-1945.DOI:10.3969/j.issn.1007-9572.2014.17.005.
|
| [17] |
张洁,梁明斌,何青芳,等. 农村社区门诊糖尿病筛查效果与成本效果分析[J]. 中国农村卫生事业管理,2015,35(1):69-71. DOI:10.19955/j.cnki.1005-5916.2015.01.025.
|
| [18] |
赵春艳,张盼,石春雷,等. 糖化血红蛋白检测在我国糖尿病前期筛检中的应用进展[J]. 中国糖尿病杂志,2017,25(12):1147-1149. DOI:10.3969/j.issn.1006-6187.2017.12.019.
|
| [19] |
陈桥英. 空腹血糖、糖化血红蛋白联合检测对体检人群中糖尿病早期筛查诊断的价值[J]. 黑龙江医药,2023,36(2):428-431. DOI:10.14035/j.cnki.hljyy.2023.02.063.
|
| [20] |
谭枝微. 空腹血糖联合糖化血红蛋白检测对糖尿病筛查的临床价值分析[J]. 糖尿病新世界,2022,25(15):61-63,67. DOI:10.16658/j.cnki.1672-4062.2022.15.061.
|
| [21] |
|
| [1] | YANG Xinying, WANG Kairong, LI Jun, YE Fanting, WANG Mengyao, LI Binbin. Analysis of the Current Situation and Influencing Factors of Gastric Precancerous Conditions in Opportunistic Screening Populations [J]. Chinese General Practice, 2026, 29(32): 4716-4720. |
| [2] | TANG Haoqing, LI Mingyue, LONG Ren, ZHU Yinbo, LIANG Weihuan, ZHU Ping, ZHAO Wei, ZHAO Yang, LIU Xiaoyun. Management Burden of Diabetic Mellitus Patients with Multimorbidity among Middle Aged and Older Adults: a Cross-sectional Survey in 6 Community Medical Institutes of China [J]. Chinese General Practice, 2026, 29(32): 4786-4797. |
| [3] | XIE Yuanling, CHENG Li, LONG Xiangyu, SU Zhengxin, SU Yiyi, ZHANG Renyue, SUN Guoqiang, CHEN Xuxia, ZHOU Jilan. Effectiveness of an AI-powered Ophthalmic Telemedicine Diagnostic Platform in Community Eye Health Screening [J]. Chinese General Practice, 2026, 29(31): 4641-4649. |
| [4] | TIAN Xiangyang, ZHOU Yingsheng, GAO Ying. Prospects of Behavioral and Lifestyle Interventions for Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(31): 4513-4520. |
| [5] | XIAO Zhili, LU Chenxia, ZHU Hui, ZHANG Jia, CHEN Zhuangzhuang, SUN Wei, LIU Xiangchuxuan, LUO Cheng, XIAO Mingzhong, LI Xiaodong. Application and Future Prospects of CGM Technology in Co-management of MAFLD and T2DM [J]. Chinese General Practice, 2026, 29(31): 4521-4527. |
| [6] | ZHAO Jiayi, FAN Jian, YU Dehua. The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry [J]. Chinese General Practice, 2026, 29(30): 4366-4371. |
| [7] | YAN Ziwei, NIE Jiahua, SHI Yan, WEI Limin. Correlation between the Albumin/Gamma-glutamyl Transferase Ratio and Metabolic-associated Fatty Liver Disease in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(30): 4431-4437. |
| [8] | ZHAO Peizhen, ZHAO Zhendong, XU Haizhu. Exploratory Study on Screening of Multiple Inherited Metabolic Disorders in Newborns in Hainan Province [J]. Chinese General Practice, 2026, 29(30): 4438-4444. |
| [9] | WANG Lin, CAO Chenchen, HUANG Yichong, LIU Jing. Development of Preference Attributes and Levels of Family Doctor Contract Services for Patients with Comorbidity of Hypertension and Type 2 Diabetes Mellitus Based on Discrete Choice Experiments [J]. Chinese General Practice, 2026, 29(29): 4232-4240. |
| [10] | ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336. |
| [11] | JIANG Chen, AN Ni, XU Yunjing, NIU Shaona, LI Fengming, JIANG Liangmei. A Cross-sectional Study of Hospitalization Characteristics and Healthcare Resource Consumption of Patients with Cardiovascular-kidney-metabolic Syndrome [J]. Chinese General Practice, 2026, 29(28): 4172-4178. |
| [12] | YU Xinyan, ZHANG Fang, GU Zhile, WANG Yanfang, SU Peng, ZHANG Haicheng. Correlation between Fasting Plasma Glucose, Body Mass Index, and Waist Circumference among Community-dwelling Elderly Individuals [J]. Chinese General Practice, 2026, 29(28): 4132-4140. |
| [13] | QU Furong, JIN Jiaqi, XUE Guijun, LYU Qingguo, LI Zhipeng, LI Jing, LI Sheyu. Interpretation of the BMJ Living Clinical Practice Guideline on Pharmacological Management of Type 2 Diabetes Based on Cardiovascular-renal Event Prevention and Weight Management [J]. Chinese General Practice, 2026, 29(27): 3873-3878. |
| [14] | WU Yuqiong, CHU Xiangling, HUANG Youye, SUN Li, JIANG Tian, ZHANG Qiu, HU Honglin. A Case Report and Literature Review of Hepatocyte Nuclear Factor 4α Gene Mutation Leading to Maturity-onset Diabetes of the Young [J]. Chinese General Practice, 2026, 29(27): 4011-4015. |
| [15] | PAN Hao, QIU Yong, LIU Rongmei, GUO Zhiping, DAI Nengguang, JIN Tong, SANG Yanhong, LI Yi, LIAO Lijuan. Impact of Basic Public Health Service Management on Hospitalization Economic Burden and Survival Outcomes in Patients: a Study of Hospitalized Patients with Diabetes [J]. Chinese General Practice, 2026, 29(25): 3599-3607. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||